Humana (HUM) has drawn investor attention after two recent developments. The company expanded its Indiana home-based care initiative with HealthStream and appointed James “J.P.” Holland to lead its Medicaid business.

Humana's recent Indiana home-based care expansion and the appointment of J.P. Holland come as the stock trades at US$382.00, with a 90 day share price return of 25.62% and a year to date share price return of 44.43%. The 1 year total shareholder return of 34.44% contrasts with declines over the 3 and 5 year total shareholder return periods, suggesting that recent momentum has picked up after a weaker longer term experience.

If Humana's recent moves in healthcare have your attention, it can be useful to scan other healthcare related opportunities using our screener focused on 42 healthcare AI stocks

Humana's shares have already moved sharply over the past year, yet the business is still investing in home-based care and Medicaid leadership. Is it worth accepting today’s price or does it make more sense to wait for a better entry point?

Most Popular Narrative: 23.9% Overvalued

Humana's most followed narrative puts fair value at $308.33, compared with the recent $382.00 close. This sets up a clear gap for investors to weigh.

The analysts have a consensus price target of $308.33 for Humana based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $441.0, and the most bearish reporting a price target of just $195.0.

Want to see why this narrative still lands below today’s share price? The key moving parts are future earnings growth, profit margins and the profit multiple embedded in the model.

Result: Fair Value of $308.33 (OVERVALUED)

However, Humana's story could change quickly if Medicare Advantage Stars outcomes or medical cost trends move against current assumptions and compress already thin margins.

Another View On Humana's Valuation

While the analyst narrative suggests Humana is 23.9% overvalued relative to a fair value of $308.33, the SWS DCF model points in the opposite direction. In this view, the stock at $382.00 trades well below an estimated future cash flow value of $1,002.13, which raises a very different question for investors.

Next Steps

The mixed signals around Humana's value and outlook may leave you torn, so consider reviewing the details promptly and weighing both sides with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Humana?

If Humana has sharpened your focus on opportunities in healthcare, do not stop here. Broadening your watchlist now can help you spot potential ideas earlier.

• Target resilient companies with steadier profiles by reviewing 79 resilient stocks with low risk scores as a starting point for your next watchlist additions.
• Hunt for quality at appealing prices by scanning 50 high quality undervalued stocks before the crowd fully catches on.
• Strengthen your income candidates by checking 11 dividend fortresses so you do not overlook yields that may fit your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.